{"id":"NCT02915744","sponsor":"Nektar Therapeutics","briefTitle":"A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine","officialTitle":"A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11","primaryCompletion":"2020-07","completion":"2020-07","firstPosted":"2016-09-27","resultsPosted":"2021-08-27","lastUpdate":"2023-04-14"},"enrollment":178,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastasis","Breast Cancer"],"interventions":[{"type":"DRUG","name":"NKTR-102","otherNames":[]},{"type":"DRUG","name":"Eribulin","otherNames":[]},{"type":"DRUG","name":"Ixabepilone","otherNames":[]},{"type":"DRUG","name":"Vinorelbine","otherNames":[]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Nab-paclitaxel","otherNames":[]}],"arms":[{"label":"NKTR-102","type":"EXPERIMENTAL"},{"label":"Treatment of Physician's Choice (TPC)","type":"ACTIVE_COMPARATOR"}],"summary":"This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).","primaryOutcome":{"measure":"Overall Survival (OS) of Patients","timeFrame":"Within 3 years from study start","effectByArm":[{"arm":"NKTR-102","deltaMin":7.8,"sd":null},{"arm":"Treatment of Physician's Choice (TPC)","deltaMin":7.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":18},"locations":{"siteCount":56,"countries":["United States","Australia","Belgium","Canada","France","Israel","Italy","Portugal","Spain","United Kingdom"]},"refs":{"pmids":["35552364","31074641"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":90},"commonTop":["Nausea","Diarrhea","Fatigue","Vomiting","Decreased Appetite"]}}